CHIR99021 dihydrochloride

For research use only. Not for therapeutic Use.

  • CAT Number: I047611
  • CAS Number: 2109414-84-6
  • Molecular Formula: C22H18Cl2N8.2HCl
  • Molecular Weight: 538.26
  • Purity: ≥95%
Inquiry Now

Very potent and specific glycogen synthase kinase GSK-3 inhibitor; highly recommended tool. Water soluble hydrochloride salt of CHIR99021 (Axon 1386, parent molecule)
* CHIR99021 and PD0325901 (Axon 1408) are often used together as 2i in stem cell research (Axon 2128).
*Promotion: Buy 2i inhibitor set | Axon 2128.
Prime Source Information: CHIR99021 from Axon Medchem has been procured by many labs as drug standard for generating reliable and reproducible biological data, evidenced by many recent publications (>750 citations). It is pure not only chemically but also biologically.
KEYWORDS: CHIR99021 hydrochloride | supplier | GSK-3 inhibitor | CT99021 hydrochloride | Laduviglusib dihydrochloride | supplier | CHIR-99021 | CHIR 99021 | CT-99021  | CT 99021 | CAS [1782235-14-6] | [1797989-42-4] | [252917-06-9] | Phosphorylation | GSK-3 | Inhibitor | water soluble | glycogen synthase kinase | stem cell | pluripotent | differentitaion | proliferation | dedifferentiation | cardiac


Catalog Number I047611
CAS Number 2109414-84-6
Molecular Formula C22H18Cl2N8.2HCl
Purity ≥95%
IUPAC Name 6-[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethylamino]pyridine-3-carbonitrile;dihydrochloride
InChI InChI=1S/C22H18Cl2N8.2ClH/c1-13-10-29-21(31-13)17-12-30-22(32-20(17)16-4-3-15(23)8-18(16)24)27-7-6-26-19-5-2-14(9-25)11-28-19;;/h2-5,8,10-12H,6-7H2,1H3,(H,26,28)(H,29,31)(H,27,30,32);2*1H
SMILES CC1=CN=C(N1)C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)Cl)NCCNC4=NC=C(C=C4)C#N.Cl.Cl
Reference

C Tong et al. Generating gene knockout rats by homologous recombination in embryonic stem cells. Nature Protocols 2011, 6, 827–844.

 

M Kawamata and T Ochiya. Generation of genetically modified rats from embryonic stem cells. PNAS 2010, 107(32), 14223-14228.

 

MY Chang et al. Direct Reprogramming of Rat Neural Precursor Cells and Fibroblasts into Pluripotent Stem Cells. PLoS One. 2010, 5(3), e9838.

 

IM Aparicio et al. Identification and regulation of glycogen synthase kinase-3 during bovine embryo development. Reproduction 2010, 140, 83-92.

 

B Zimmer et al. Coordinated waves of gene expression during neuronal differentiation of embryonic stem cells as basis for novel approaches to developmental neurotoxicity testing. Cell Death and Differentiation. 2011, 18, 383–395.

 

Q.L.Ying et al. The ground state of embryonic stem cell self-renewal. Nature. 2008, 453, 519-523.

 

J. Bain et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408, 297-315.

 

D.B. Ring et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003, 52, 588-595.

 

A.S. Wagman et al. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des. 2004, 10, 1105-1137.

 
List of publications using CHIR99021 (Axon 1386 or Axon 2435) purchased from Axon Medchem

Request a Quote